CKCecilia Katzenstein

Cecilia Katzenstein

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Cecilia Katzenstein has a total of 51 co-authors. Here are the top co-authors by number of shared publications:

  • Nina Rodriguez

    Icahn School of Medicine at Mount Sinai, New York, NY, USA

    4 shared publications
  • Tatyana Kushner

    Department of Gastroenterology and Hepatology, Weill Cornell Medicine, New York, New York, USA

    4 shared publications
  • Lauren Alpert

    Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA

    3 shared publications
  • Nina Rodriguez

    Icahn School of Medicine at Mount Sinai, New York, NY, USA

    2 shared publications
  • Tatyana Kushner

    Division of Gastroenterology and Hepatology, Division of Obstetrics and Gynecology, Weill Cornell Medicine, New York, New York, USA

    2 shared publications
  • Alison Lee

    Department of Medicine, Division of Pulmonary, Critical Care, and Sleep Medicine, Icahn School of Medicine at Mount Sinai, New York, NY. (A.L.)

    1 shared publication

Latest Publications

  • Dysglycemia and Adverse Pregnancy Outcomes Among Individuals with Polycystic Ovary Syndrome

    by Cecilia Katzenstein, Nina Rodriguez, Marcia Lange, Jeanette Rios, Rachel Meislin, Keith Sigel, Emily J. Gallagher, Rhoda Sperling, Norah Terrault, Joanne Stone, et al.

    Background: Polycystic ovary syndrome (PCOS) has been associated with adverse pregnancy outcomes, although reported risks vary across studies. Metabolic heterogeneity within PCOS may contribute to this variability. Dysglycemia during pregnancy may identify a subgroup at increased obstetric risk. The study aims to evaluate whether dysglycemia is associated with preeclampsia and other adverse pregnancy outcomes among individuals with PCOS. Methods: We performed a secondary analysis of the prospective Fatty Liver in Pregnancy (FLIP) cohort ( n = 1,321). PCOS was defined by chart review of the electronic health record. Dysglycemia was defined as current or prior gestational diabetes, abnormal glucose tolerance testing, hemoglobin A1c > 5.7% during pregnancy, or pregestational diabetes. Participants were categorized as PCOS with dysglycemia ( n = 36), PCOS without dysglycemia ( n = 44), or non-PCOS controls ( n = 1,238). The primary outcome was preeclampsia. Secondary outcomes included gestational hypertension, preterm birth, abnormal neonatal weight, and neonatal hypoglycemia. Multivariable logistic regression adjusted for maternal age and body mass index. Results: Among 80 individuals with PCOS, 45% had evidence of dysglycemia. Preeclampsia occurred in 33% of those with PCOS and dysglycemia, 7% of those with PCOS without dysglycemia, and 12% of controls ( p = 0.005 for PCOS with dysglycemia versus controls). In adjusted analyses, PCOS with dysglycemia was associated with preeclampsia (odds ratio [OR] 2.9; 95% confidence interval [CI]: 1.4–6.1), whereas PCOS without dysglycemia was not (adjusted odds ratio [aOR] 0.53; 95% CI: 0.16–1.73). PCOS with dysglycemia was also associated with increased preterm birth (OR: 2.3; 95% CI: 1.04–5.14), abnormal neonatal weight (OR: 2.87; 95% CI: 1.36–6.10), neonatal hypoglycemia (OR: 2.8; 95% CI: 1.38–5.77), and any adverse pregnancy outcome (aOR: 4.49; 95% CI: 1.94–10.40). Conclusions: In this prospective cohort, dysglycemia was associated with higher rates of hypertensive and metabolic pregnancy complications among individuals with PCOS. These findings suggest that coexisting dysglycemia may contribute to heterogeneity in obstetric risk among individuals with PCOS and warrant confirmation in larger studies.

  • End-of-Life Decision Making in Internal Medicine: A Retrospective Cohort Study of Clinical Ethics Consultations

    by Cecilia Katzenstein, Regina M. Longley, Robert M. Arnold, Krishna Chokshi

    Internal Medicine physicians frequently face complex ethical dilemmas in end-of-life (EOL) care, particularly when prognoses are uncertain and patients lack decisional capacity, surrogate representation, or clear care preferences. Clinical Ethics Consultations (CECs) can provide support, yet little empirical data describe how Internal Medicine teams utilize CEC services. To characterize the clinical features, ethical themes, and recommendations of CECs requested by Internal Medicine services, particularly in the context of EOL care. Retrospective cohort study using structured chart review and qualitative analysis. Single large, urban, academic referral hospital with a multidisciplinary ethics consultation service. Adult inpatients who received a clinical ethics consultation between January 1, 2018, and December 31, 2022 (N = 216). Receipt of a clinical ethics consultation. Primary ethical themes, subthemes, and recommendations were identified using the Armstrong Clinical Ethics Coding System. Ethics recommendations were also categorized by theme. Of 216 total consultations, 139 (64%) were requested by Internal Medicine services, including 86 (62% of IM consults) from Hospital Medicine. Mean patient age was 62.7 years (SD 15.6); 62% were male. Twenty-six percent (n = 36) lacked decisional capacity and representation. Among Internal Medicine CECs, 53% (n = 74) addressed EOL care. Common subthemes included futility/inappropriate or non-beneficial treatment (56%, n = 41), artificial nutrition and hydration (29%, n = 21), and withholding/withdrawing life-sustaining treatment (29%, n = 21). Recommendations included non-escalation (36%, n = 27), continuation of treatment (34%, n = 25), and goal clarification (38%, n = 28). Palliative care was consulted as a separate clinical service and involved in patient care prior to or concurrently with the ethics consultation in 35% (n = 49) of IM cases, and 49% (n = 68) of patients died during hospitalization. Single-center design and lack of qualitative data from requesting clinicians. CECs often support complex EOL decision-making in Internal Medicine. Subthemes like futility and artificial nutrition influence recommendations in distinct ways, underscoring ethics' role in navigating uncertainty and supporting patient-centered care.


  • Evaluating the 2023 European Association for the Study of the Liver Guidelines for Intrahepatic Cholestasis of Pregnancy: Risk Stratification and Outcomes in Over 4,000 US Patients

    by Nina Rodriguez, Cecilia Katzenstein, Lauren Alpert, Keith Sigel, Rhoda S. Sperling, Catherine Williamson, Tatyana Kushner

    INTRODUCTION: Intrahepatic cholestasis of pregnancy (ICP) is the most common liver disease of pregnancy, varying in incidence based on population and associated with adverse outcomes. We assessed the prevalence and outcomes of ICP categories defined by the 2023 European Association for the Study of the Liver guidelines in a diverse US population. METHODS: We conducted a retrospective cohort study (January 2009–April 2024) at our ethnically diverse health system. Suspected ICP patients were identified by pregnancy records with total serum bile acids (TSBA) ordered and categorized into Group A (normal TSBA, alanine aminotransferase [ALT]/aspartate aminotransferase [AST]), B (elevated ALT/AST, normal TSBA), or C (TSBA >19, normal or elevated ALT/AST). RESULTS: Among 165,503 pregnancies, we identified 4,386 (3.6%) suspected ICP cases. The cohort was classified as A (65%), B (24%), or C (11%). On multivariable analysis, a pre-existing history of autoimmune disease, metabolic dysfunction-associated steatotic liver disease, and gestational hypertension were significantly associated with Group B compared with A. Group C was more strongly associated with Hispanic ethnicity, history of hepatitis C, and immune-mediated liver diseases. Preeclampsia was 3 times as common in Groups B and C compared with A. Group C had the highest odds of spontaneous preterm birth, meconium-stained amniotic fluid, and neonatal respiratory distress. Group B and C had higher rates of incident postpartum hepatobiliary diseases. DISCUSSION: Our systematic evaluation of the 2023 European Association for the Study of the Liver guidelines for suspected ICP demonstrated that this novel group-based classification offers clinically meaningful risk stratification. Our findings support that both elevated TSBA (Group C) and elevated ALT/AST alone (Group B) warrant antepartum surveillance for adverse pregnancy outcomes. Group C's association with Hispanic ethnicity and pre-existing liver disease highlights the need for individualized monitoring during pregnancy. Group-specific increased incidence of postpregnancy hepatobiliary disease emphasizes the importance of targeted postpartum follow-up.

  • Novel Implementation of Hepatitis B to Hepatitis Delta Reflex Testing in a US Healthcare System

    by Anna Mageras, Nina Rodriguez, Cecilia Katzenstein, Frances Lee, Lauren Alpert, Andrea D. Branch, Xiaotao Zhang, Douglas T. Dieterich, Tatyana Kushner

    INTRODUCTION: Hepatitis delta virus (HDV) is the most aggressive form of viral hepatitis, yet screening rates in the United States are low, and few institutions have attempted interventions to improve the screening cascade. We assessed barriers to reflex test implementation, including lack of a Food and Drug Administration-approved reflex test, and implemented hepatitis B surface antigen (HBsAg) to HDV antibody (HDV Ab) reflex testing in our large, urban, academic healthcare system. METHODS: We evaluated outcomes 1 year after implementation using summary statistics. Patient-level and clinic-level characteristics were investigated for association with receiving a reflex test vs standalone HBsAg test using multivariable logistic regression. RESULTS: All patients with a reflex order and HBsAg-positive result received HDV Ab follow-up testing, and their time to HDV Ab result was significantly shorter than those whose HDV test required a separate order (2 vs 11 days, P < 0.0001). Uptake of the reflex order was highest in primary care, where it was embedded into existing workflows. DISCUSSION: Reflex testing improved efficiency and reduced gaps in the HBsAg to HDV screening cascade. Disparities in reflex testing rates among different patient groups were found, highlighting the need for universal reflex testing.


  • Translating Hepatitis D Virus Screening Cost-Effectiveness into Practice: The Case for Reflex Testing in the United States

    by Cecilia Katzenstein, Anna Mageras, Nina Rodriguez, Frances Lee, Lauren Alpert, Andrea D Branch, Xiaotao Zhang, Douglas T Dieterich, Tatyana Kushner


  • Challenges in applying MASLD risk algorithms in pregnancy: A call for adaptation and inclusion

    by Nina Rodriguez, Cecilia Katzenstein, Marcia Lange, Jeanette Rios, Tatyana Kushner, Fatty Liver in Pregnancy (FLIP) Study Group


  • Racism and Postpartum Blood Pressure in a Multiethnic Prospective Cohort

    by Teresa Janevic, Frances M. Howell, Micki Burdick, Sarah Nowlin, Sheela Maru, Natalie Boychuk, Oluwadamilola Oshewa, Maria Monterroso, Katharine McCarthy, Daniel A. Gundersen, et al.

    BACKGROUND: Postpartum hypertension is a key factor in racial-ethnic inequities in maternal mortality. Emerging evidence suggests that experiences of racism, both structural and interpersonal, may contribute to disparities. We examined associations between gendered racial microaggressions (GRMs) during obstetric care with postpartum blood pressure (BP). METHODS: We conducted a prospective postpartum cohort of 373 Asian, Black, and Hispanic people in New York City and Philadelphia. At delivery, we administered the GRM in obstetrics scale. We measured BP for 3 months using text-based monitoring. We estimated place-based structural racism with the Structural Racism Effect Index. We used mixed models to estimate associations between GRM and mean postpartum systolic BP and diastolic BP. We adjusted for race-ethnicity, education, body mass index, chronic hypertension (diagnosed at <20 weeks of gestation), age, and the Structural Racism Effect Index. We examined effect modification by hypertensive disorder of pregnancy and place-based structural racism. RESULTS: A total of 4.6% of participants had chronic hypertension, 20.9% had pregnancy hypertension, and 13.4% had preeclampsia, comprising a hypertensive disorder of pregnancy subgroup (n=117). A total of 37.5% of participants experienced ≥1 GRM. Participants who experienced ≥1 GRM versus none had 1.88 mm Hg higher systolic BP from days 1 to 10 (95% CI, −0.19 to 3.95) and 2.19 mm Hg higher systolic BP from days 11 to 85 (95% CI, 0.17–4.22). Associations followed a similar pattern for diastolic BP and were stronger among the hypertensive disorder of pregnancy subgroup. Participants experiencing GRM and a high Structural Racism Effect Index had systolic BP 7.55 mm Hg (95% CI, 3.41–11.69) and diastolic BP 6.03 mm Hg (95% CI, 2.66–9.41) higher than those with neither. CONCLUSIONS: Structural racism and interpersonal racism are associated with increased postpartum BP, potentially contributing to inequities in postpartum morbidity and mortality and lifecourse cardiovascular disease.